B002 in Patients With HER2-positive Breast Cancer
To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.
Recurrent Breast Cancer|Metastatic Breast Cancer
BIOLOGICAL: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.
Maximum Tolerated Dose (MTD), 21 days|Dose-Limiting Toxicity (DLT), 21 days
Tmax, Pharmacokinetics measurement, 21 days|Cmax, Pharmacokinetics measurement, 21 days|AUC, Pharmacokinetics measurement, 21 days|Anti-drug antibody (ADA), through study completion, an average of 2 years|Objective Remission Rate (ORR), Therapeutic Efficacy, through study completion, an average of 2 years
To assess the safety and tolerability characteristics of B002 in patients with HER2-positive recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) was assessed and the maximum tolerated dose (MTD) was explored.